Principal Financial Group Inc X4 Pharmaceuticals, Inc Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$0.54 - $0.86 $6,838 - $10,891	-12,664 Reduced 40.32%	18,746 $12,000
Q2 2024 Jul 29, 2024	BUY	$0.58 - $1.47 $10,277 - $26,046	17,719 Added 129.42%	31,410 $18,000
Q1 2024 Apr 29, 2024	SELL	$0.72 - $1.46 $2,113 - $4,285	-2,935 Reduced 17.65%	13,691 $19,000
Q4 2023 Feb 07, 2024	BUY	$0.61 - $0.99 $182 - $296	299 Added 1.83%	16,626 $13,000
Q3 2023 Nov 02, 2023	BUY	$1.03 - $2.02 $2,598 - $5,096	2,523 Added 18.28%	16,327 $17,000
Q2 2023 Aug 07, 2023	BUY	$0.82 - $2.49 $11,319 - $34,371	13,804 New	13,804 $26,000

103

99.9M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $41.9M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.